|drug1586||lung ultrasound Wiki||0.58|
|drug1259||Sodium Nitrite Wiki||0.58|
|drug1335||Symptoms questionnare Wiki||0.58|
|drug914||Normal Saline Wiki||0.58|
|drug1474||VitalConnect Vital Sign Patch Wiki||0.58|
|drug253||COVID-19 Serology Wiki||0.41|
|D020181||Sleep Apnea, Obstructive NIH||0.58|
|D012891||Sleep Apnea, NIH||0.58|
|D001145||Arrhythmias, Cardiac NIH||0.41|
|D055370||Lung Injury NIH||0.13|
|D055371||Acute Lung Injury NIH||0.07|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.07|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.06|
There are 3 clinical trials
The 2019-20 coronavirus disease, caused by COVID-19, is an ongoing pandemic. The measures in which public health officials quarantine confirmed and isolate symptomatic cases in order to reduce the spread COVID-19 is the common practice used in most countries. However, a significant question remains in regards to the asymptomatically infected individuals, which may propagate the virus and impede infection control. The other question to consider is whether these asymptomatic carriers develop an immune response or continue viral shedding. The purpose of the current study is the evaluate the immune response, i.e developing anti-SARS-CoV-2 antibodies in the asymptomatic cases, in a household study design. We plan to evaluate over 1000 patients with positive COVID-19 results and their households.
Description: The percentage of symptomatic patients who developed either IgM/IgG/IgA response within 100 days from COVID-19 InfectionMeasure: Proportion of symptomatic patients with immune response (IgM/IgG/IgA) Time: 100 days
Description: The percentage of Asymptomatic patients who developed either IgM/IgG/IgA response within 100 days from COVID-19 InfectionMeasure: Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA) Time: 100 days
Description: the mean time patients devleoped IgMMeasure: Time to IgM Time: Evaluated within a 100 days followup
Description: the mean time patients devleoped IgGMeasure: Time to IgG Time: Evaluated within a 100 days followup
Description: the mean time patients devleoped IgGMeasure: Time to IgA Time: Evaluated within a 100 days followup
Description: Cohen's kappa coefficient calculated between the different serology kits used for evaluationMeasure: Serology kits inter-observer agreement Time: Evaluated within a 100 days followup
The objective of study is to estimate the sensitivity and specificity of the COR-DIAL based on nasopharyngeal samples taken at the patient's admission in relation to the final diagnosis of COVID-19 made by the medical team.
Covid-19 (English acronym meaning coronavirus disease 2019) is an emerging infectious disease caused by a strain of coronavirus called SARS-CoV-2. The current pandemic has resulted in a significant number of admissions in the emergency room (ER) due to suspicion of COVID-19 infection. Use of lung ultrasound is standard practice to diagnose acute respiratory failure in ER. Recently, typical lung ultrasonographic characteristics of COVID-19 disease has been described. During the COVID-19 pandemic, the use of this tool could be of interest in order to allow an early, simple and reliable triage in patients with suspected COVID-19 infection admitted in ER. In addition, the visualization of early signs in specific areas could be a predictive marker of the severity of the disease. The objective of this project will be to study the association between the signs on lung ultrasound and the result of RT-PCR in patients with suspected COVID-19 infection in the ER.
Description: Polymerase chain reaction tests after reverse transcription for the detection of covid-19 viral RNA will be done as biological test.Measure: Lung ultrasound/biological correlation research modulating the severity of Covid-19 disease Time: 6 months